Search
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269ApprovedDichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. … [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]
Mixtures: ซีพาคอล(R) อาร์เอ็กซ์, ซีพาคอล(R) อาร์เอ็กซ์Levorphanol
go.drugbank.com/drugs/DB00854ApprovedA narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.
Categories: Heterocyclic Compounds with 4 or More RingsInotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalInotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … Hereditary transthyretin amyloidosis is caused by single-nucleotide variants in the gene encoding transthyretin (TTR), which lead to transthyretin misfolding and the deposition of amyloid substance systemically
Cyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.
Mixtures: DOBRIX ®, Therabenzaprine-90-5Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: TAFINLAR®75 MG CÁPSULAS DURAS, TAFINLAR® 50 MG CÁPSULAS DURASAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). … Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin
Products: EYLIA® SOLUCIÓN PARA INYECCIÓN INTRAVÍTREA, ZALTRAP 100MG/4ML INFUZYONLUK KONSANTRE COZELTI İÇEREN FLAKON, 3 ADETBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalSince PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive ModulatorsAclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Mixtures: DUAKLIR®GENUAIR®340/12MCG/DOSIS.Products: EKLIRA®GENUAIR® 322 MCG/DOSISLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic IndexSynonyms: (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate, 1-alpha-AcetylmethadolElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Products: VIMIZIM® 1MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓN